Latest Neuroscientific Biopharmaceuticals (ASX:NSB) News

NeuroScientific Biopharmaceuticals has secured regulatory approval for initial patient treatments under its Special Access Program for StemSmart™ in Crohn’s disease, alongside key executive appointments and a manufacturing partnership to support upcoming clinical trials.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

NeuroScientific Biopharmaceuticals reports encouraging early clinical results for its StemSmart™ MSC therapy in preventing and treating kidney transplant rejection and injury.

NeuroScientific Biopharmaceuticals has appointed Nathan Smith as CEO, leveraging his deep cell therapy expertise to accelerate clinical development and commercialisation of its StemSmart technology.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart stem cell technology, setting the stage for a focused clinical push in treating fistulising Crohn’s disease. The company also refreshed its board and raised $7.5 million to support this next phase.

NeuroScientific Biopharmaceuticals reveals compelling clinical evidence supporting its StemSmart MSC therapy for severe steroid-refractory graft versus host disease, advancing its strategic acquisition plans.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.